Keze Yongxin, a Specialized and Innovative Supplier of Small Nucleic Acid Raw Materials, Completes Tens of Millions RMB Pre-A Financing Round

VCBeat Exclusively Learns: Supplier of High-Quality Small Nucleic Acid Raw Material ProductsShanghai Kezx Biotechnology Co.,Ltd(hereinafter referred to as “Kezx”) announced the completion of a financing round amounting to tens of millions of yuan. This round of financing was led byDisheng CapitalLead Investor, Existing ShareholdersCaleb CapitalContinue to increase investment. The funds raised will be used for the construction of the production base of Anhui Kezx Yongxin Biotechnology Co., Ltd., a wholly-owned subsidiary.

Kezx, founded in 2023 and led by a team of PhDs and postdoctoral researchers from ETH Zurich, is a high-tech enterprise specializing in the R&D of core backbone raw materials and auxiliary substances for oligonucleotides, as well as the production of related products. The company has been recognized with multiple qualifications, including “High-Tech Enterprise” and “Specialized, Refined, Differential, and Innovative (SRDI) Enterprise.”

Leveraging the core team’s extensive experience in chemical synthesis and nucleic acid drug delivery system development, along with in-depth research into downstream markets, Kezx has continuously optimized its internal control metrics and established a high-quality key technology platform.The company focuses on nucleotide monomers and phosphoramidites. Its delivery systems include the GalNAc series (such as L96, NAG25, NAG37, and NAG52), as well as extrahepatic delivery platforms comprising AOC-series linkers, renal-targeted delivery, and lung-targeted delivery.

Regarding the completion of this round of financing,Dr. Kun Zhang, Founder of the CompanyHe stated, “The global development of oligonucleotide therapeutics has accelerated rapidly in recent years, with numerous Chinese pharmaceutical companies and biotech firms entering this field. Kezx has grown alongside this sector. We extend our gratitude to our customers for their trust and to our investors for their strong support. Upholding our motto, ‘Pursuing Science, Benefiting the World,’ we continuously improve the quality of our upstream raw materials, facilitate the R&D and market launch of more oligonucleotide drug pipelines, and contribute to the advancement of human health.”

Dr. Ying Liu, Founding Partner of Disheng Capital“It has been stated that, leveraging three core advantages, small nucleic acid drugs have become a highly promising and significant track in the biopharmaceutical sector. First, they feature shorter R&D cycles and significantly higher success rates compared to traditional drugs. Second, they offer durable and stable efficacy with a low propensity for inducing drug resistance, highlighting their substantial clinical value. Third, they cover a broader range of targets, thereby overcoming the R&D limitations of conventional therapeutics. With the successful global launch of multiple blockbuster small nucleic acid drugs, this field has garnered considerable industry attention. It has not only attracted numerous emerging biotech companies to establish deep footholds but also prompted large pharmaceutical companies to increase their investments. Furthermore, clinical indications are gradually expanding from rare diseases to various common chronic conditions. As the global and Chinese pipelines for small nucleic acid drugs become increasingly robust, the market presents vast development space and prominent opportunities.”

Dr. Liu Ying further pointed out, “As a core raw material supplier in the small nucleic acid drug sector, Kezx has accumulated a strong market reputation and user recognition within the industry, thanks to its significant technological barriers, robust R&D and innovation capabilities, diverse product pipeline, and reliable product quality. Led by Dr. Zhang Kun, the management team has demonstrated clear strategic planning and strong execution, driving the company’s rapid business growth. As the lead investor in this round of financing for Kezx, Disheng Capital will fully support the company in expanding production capacity and accelerating development, helping it further consolidate its industry position, promote the high-quality development of China’s small nucleic acid drug industry, address more unmet clinical needs, and inject new momentum into the innovation and upgrading of the biopharmaceutical industry.”

Dr. Gao Du, Vice President of Investment at Caleb CapitalWe are pleased to announce our additional investment in Kezx, a key upstream supplier of raw materials for oligonucleotide therapeutics. The company specializes in modified monomers and delivery vectors, achieving international leading standards in both quality and variety. Over the past three years, it has scaled from milligram-level R&D to commercial supply capabilities. Kezx is also expanding its oligonucleotide drug CRO platform and accelerating its global layout. We are confident in the enterprising spirit and pursuit of excellence demonstrated by Mr. Zhang Bo and his team, as the company continues to support the clinical development of an growing pipeline of innovative oligonucleotide therapies.

Oligonucleotide therapeutics are transitioning from a “blue ocean” market into the “deep waters of commercialization,” with upstream raw materials representing the core bottleneck in the industry chain. We have not only established a presence in upstream raw materials but also invested in enterprises focused on innovative oligonucleotide drug pipelines, creating a synergistic full-industry-chain model of “raw materials + innovative drugs.” This round of financing will accelerate the company’s capacity expansion and empower the rise of China’s oligonucleotide industry.

Disheng Capital is a professional investment institution focused on the life and health industry, with a core strategic layout in the field of anti-aging. It deeply cultivates anti-aging-related sectors by covering the entire value chain of biological age assessment for the human body and key organs, as well as aging prevention, intervention, and treatment. Committed to driving technological innovation and industrial implementation in the anti-aging field through capital and industrial empowerment, Disheng Capital aims to address unmet medical and healthcare needs by delaying and reversing the aging process.

Disheng Capital’s investment portfolio spans core sectors across the value chain, including in vitro diagnostics, synthetic biology, nutrition and health supplements, medical devices, and biopharmaceuticals. The firm primarily focuses on early- and growth-stage enterprises driven by cutting-edge technologies. It strategically balances its portfolio by investing in high-quality projects capable of rapid commercialization and profitability, while also allocating capital to innovative ventures with longer development cycles but significant potential for high growth and returns.

Leveraging the management team’s profound industry expertise, extensive industrial resources, and systematic post-investment management capabilities, Disheng Capital continuously provides comprehensive empowerment to its portfolio companies. It helps them overcome technical bottlenecks and expand their industrial scale, while building a highly synergistic and sustainable ecosystem for the life and health industry. By promoting technology transfer and industrial upgrading in the field of anti-aging, Disheng Capital delivers more valuable healthcare solutions to the market.

Caleb Capital is an emerging, specialized investment management firm focused on growth-stage enterprises in China, distinguished by its provision of “best-in-class value-added services.” The firm specializes in the healthcare and related sectors. Guided by the principles of “respect, integrity, responsibility, and professionalism,” Caleb Capital’s investment management team collaborates openly with portfolio company entrepreneurs and fund investors. Leveraging the team’s highly specialized value-added service capabilities, the firm facilitates value discovery and value enhancement for its portfolio companies.

Caleb Capital’s investors include listed companies in China and overseas, market-oriented funds of funds (FOFs), international investment bankers, China Top 500 enterprises, distinguished entrepreneurs, and professional investors. They will foster robust industrial interaction and experience sharing with portfolio companies, while providing global perspectives and resources.

Caleb Capital’s vision and mission are “to invest in entrepreneurs who can become global industry leaders, and to advance human health and medical care through capital and specialized services.” Caleb Capital’s investment management team consistently adheres to the philosophy of long-term value investing and is committed to bridging the gap between financial capital and industry from an industrialization perspective, striving to become a professional investment institution that “understands industries and understands businesses.”